Treatment of depression in outpatients: a controlled comparison of the onset of action of amoxapine and maprotiline.
In a 4-week double-blind study, amoxapine and maprotiline were compared in the treatment of 76 outpatients with moderate to severe depressive illness. Mean maximum daily dosages were 230 mg for amoxapine and 165 mg for maprotiline. The data suggest that in these dosages amoxapine and maprotiline are equally effective overall. However, significant differences favored amoxapine at Days 4 and 7, in agreement with other studies showing early onset of therapeutic action of amoxapine.
D000328:Adult; D000553:Ambulatory Care; D000657:Amoxapine / Q000627:therapeutic use*; D000873:Anthracenes / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D003989:Dibenzoxazepines / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008376:Maprotiline / Q000627:therapeutic use*; D010352:Patient Dropouts; D010555:Personality Inventory; D011569:Psychiatric Status Rating Scales; D013997:Time Factors
D000873:Anthracenes; D003989:Dibenzoxazepines; D008376:Maprotiline; D000657:Amoxapine